Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Allogeneic Hematopoietic Blood-Cell Transplantation As Immunotherapy for Metastatic Renal Cell Carcinoma

  • Chapter
Cancer Immunotherapy at the Crossroads

Part of the book series: Current Clinical Oncology ((CCO))

  • 118 Accesses

Abstract

Once metastatic, the prognosis of patients with metastatic renal cell carcinoma (RCC) is extremely poor. Chemotherapy is usually ineffective, and radiotherapy is typically reserved for palliative purposes. Although most would consider RCC to be an “immunoresponsive” solid tumor, the vast majority of patients treated with systemic immunomodulators fail to manifest a disease response. Nevertheless, kidney cancer remains one of the few solid tumors to manifest evidence of intrinsic vulnerability to immune attack. As a result, considerable efforts have been made to develop methods to direct the immune system against RCC, including treatment with cytokines (e.g., interleukin [IL]-2, IL-12, interferons), the adoptive infusion tumor-infiltrating lymphocytes (TIL) or lymphocytes activated by cytokines (lymphokine-activated killer cells [LAK]) and tumor vaccine-based approaches. More recently, investigators have begun to pursue an alternative immune-based strategy in patients who fail to respond to conventional cytokines—namely, immune enhancement via total immune replacement following “low-intensity” nonmyeloablative allogeneic stem-cell transplantation (NST). NST has recently been shown to produce potent immune-mediated antitumor responses against a variety of chemotherapy-refractory hematologic malignancies, and has been associated with lower morbidity and mortality rates than conventional “mega-dose” myeloablative regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49: 8–31.

    Article  PubMed  CAS  Google Scholar 

  2. Chow WH, Devesa SS Warren JL, Fraumeni JFJ. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628–1631.

    Article  PubMed  CAS  Google Scholar 

  3. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. NEJM 1996; 335: 856.

    Article  Google Scholar 

  4. Lokich J, Harrison, JH. Renal cell carcinoma: natural history and chemotherapeutic experience. J Urol 1975; 114–371.

    Google Scholar 

  5. Linehan WM, Shipley WU, Parkinson DR. (1993) Cancer of the kidney and ureter In Cancer: Principles and Practice of Oncology, fourth ed. (Devita VT Jr., ed.) JB Lippincott, Philadelphia, PA, 1993, pp.

    Google Scholar 

  6. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma Urol Clin North Am 1993; 20: 303–314.

    PubMed  CAS  Google Scholar 

  7. Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000;(12):2419–2426.

    Google Scholar 

  8. Ryan CW, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 2002;15;94(10):2602–2609.

    Google Scholar 

  9. Bumpus HC. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol 1928; 20: 185–191.

    Google Scholar 

  10. Fairlamb DJ. Spontaneous regression of metastatic renal cell cancer. Cancer 1981; 47: 2102–2106.

    Article  PubMed  CAS  Google Scholar 

  11. Evanson TC, Cole WH (1996) Spontaneous Regression of Cancer. WB Saunders, Philadelphia, PA, pp. 11–87.

    Google Scholar 

  12. Bloom HJG (1972) Renal cancer. In Endocrine therapy of Malignant Disease. WB Saunders, Philadelphia, PA, pp. 339–367.

    Google Scholar 

  13. Gleave ME, Elhilali M, Fredet Y, et al. Interferon gamma-lb compared with placebo in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1265–1271.

    Article  PubMed  CAS  Google Scholar 

  14. Finke JH, Rayman P, Hart L, et al. Characterization of TIL subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, INF-y secretion and proliferation. J Immunother 1994; 15: 91–104.

    Article  CAS  Google Scholar 

  15. Gaugler B Brownvenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T- Lymphocytes on human renal cell carcinoma. Immunogenetics 1996; 44: 323–330.

    Article  PubMed  CAS  Google Scholar 

  16. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor Zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613–5616.

    PubMed  CAS  Google Scholar 

  17. Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of Kappa B-specific DNA binding activity: a preliminary report. Cancer Res 1994; 54: 5424–5429.

    PubMed  CAS  Google Scholar 

  18. Uzzo RG, Rayman P, Bloom T. Mechanisms of apoptosis in T-cells from patients with renal cell carcinoma. Clin Cancer Res 1999; 5: 1219–1229.

    PubMed  CAS  Google Scholar 

  19. Bukowski RM, Novick AC. Clinical practice guidelines: Renal cell carcinoma. Cleve Clin JMed 1997; 64 (Suppl 1): 1–48.

    Google Scholar 

  20. Minisian LM, Motzer RJ, Gluck L, et al. Interferon alpha 2-a in advanced remai cell carcinoma: Treatment results and survival in 159 patients with long term follow-up. J Clin Oncol 1993; 11: 1368–1375.

    Google Scholar 

  21. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80: 1198–1220.

    Article  PubMed  CAS  Google Scholar 

  22. Bukowski RM, Dutcher JP (2000) Low dose interleukin-2. In Genitourinary Oncology ( Vogelzang NJ, Scardino PT, Shipley WW, eds), Lippincott Williams & Williams, Philadelphia, PA. pp. 218–233.

    Google Scholar 

  23. Chikkala NF, Lewis I, Ulchaker J, et al. Interactive effects of alpha-interferon A/D and interleukin-2 on murine lyphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res 1990; 50: 1176–1182.

    PubMed  CAS  Google Scholar 

  24. Negrier S, Escudier B, Lasser C, et al. Recombinant human interleukin-2, recombinant interferon-alpha-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1272–1278.

    Article  PubMed  CAS  Google Scholar 

  25. Marten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 200251(11–12):637–644.

    Google Scholar 

  26. Horowitz M, Gale RP, Sondel P, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1991; 78: 2120–2130.

    PubMed  Google Scholar 

  27. Kolb HJ, Mittermueller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465

    PubMed  CAS  Google Scholar 

  28. van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977–982.

    Article  PubMed  Google Scholar 

  29. Verdonck L, Lokhorst H, Dekker A, et al. Graft-versus-myeloma effect in 2 cases. Lancet 1996; 347: 800–801.

    Article  PubMed  CAS  Google Scholar 

  30. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508.

    PubMed  CAS  Google Scholar 

  31. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986–993.

    PubMed  CAS  Google Scholar 

  32. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    PubMed  CAS  Google Scholar 

  33. Slavin S, Nagler A, Naparastak E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998; 91: 756–763.

    PubMed  CAS  Google Scholar 

  34. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98 (13): 3595–3599.

    Article  PubMed  CAS  Google Scholar 

  35. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA mismatched bone-marrow transplantation. Lancet 1999; 353: 1755–1759.

    Article  PubMed  CAS  Google Scholar 

  36. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism preceded alloimmune responses. Blood 1999;94:3234–3241.

    Google Scholar 

  37. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina Ai, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97 (11): 3390–3400.

    Article  PubMed  CAS  Google Scholar 

  38. Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26 (2): 119–125.

    Article  PubMed  CAS  Google Scholar 

  39. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613–5616.

    PubMed  CAS  Google Scholar 

  40. Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA binding activity: a preliminary report. Cancer Res 1994; 54: 5424–5429.

    PubMed  CAS  Google Scholar 

  41. Uzzo RG, Rayman P, Bloom T. Mechanisms of apoptosis in T-cells from patients with renal cell carcinoma. Clin Cancer Res 1999; 5: 1219–1229.

    PubMed  CAS  Google Scholar 

  42. Carvallo C, Kurlander R, Geller N, Griffith L, Linehan WM, Childs R. Prior chemotherapy facilitates donor engraftment following nonmyeloablative allogeneic stem cell transplantation. Blood 2002; 100 (11): 620a.

    Google Scholar 

  43. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.

    Article  PubMed  CAS  Google Scholar 

  44. Rini B, Zimmerman TM, Stadler W, et al. Allogeneic stem-cell transplantation of Renal Cell Cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Onc 2002; 20 (8): 2017–2024.

    Article  Google Scholar 

  45. Pedrazzoli P, Da Prada G, Giorgiani G, et al. Allogeneic blood stem cell transplantation after reduced intensity, preparative regimen—a pilot study in patients with refractory malignancies. Cancer 2002; 94 (9); 2409–2416.

    Article  PubMed  Google Scholar 

  46. Appelbaum FR, Sandmaier B. Sensitivity of renal cell cancer to nonmyeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important? J Clin Oncol 2002 20 (8): 1965–1967.

    PubMed  Google Scholar 

  47. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99 (11): 4234–4236.

    Article  PubMed  CAS  Google Scholar 

  48. Mena O, Igarashi T, Srinivasan R, et al. Immunologic mechanisms involved in the graft versus tumor effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation. Blood 2001; 98: 356a.

    Google Scholar 

  49. Childs RW, Mena OJ, Tykodi S, Riddell S, Warren E. Minor histocompatibility antigens (mHa) are expressed on renal cell carcinoma (RCC) cells and are potential targets for a graftvs-tumor effect (GVT) following allogeneic blood stem cell transplantation (SCT). Proceedings of the American Society of Clinical Oncology 2002; 21: 433a.

    Google Scholar 

  50. Warren EH, Tykodi SS, Murata M, et al. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy 2002: 4 (5); 441–442.

    Article  PubMed  CAS  Google Scholar 

  51. Igarashi T, Srinivasan R, Wynberg J, Takahashi Y, Becknel B, Caligiuri M, et al. Generation of allogeneic NK cells cytotoxic to melanoma and renal cell carcinoma based on killer immunoglobulin-like receptor (KIR)-ligand incompatibility. Blood 2002; 100 (I1): 620a.

    Google Scholar 

Download references

Authors
  1. Richard W. Childs MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristian A. Carvallo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    James H. Finke PhD

  2. Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA

    Ronald M. Bukowski MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Childs, R.W., Carvallo, C.A. (2004). Allogeneic Hematopoietic Blood-Cell Transplantation As Immunotherapy for Metastatic Renal Cell Carcinoma. In: Finke, J.H., Bukowski, R.M. (eds) Cancer Immunotherapy at the Crossroads. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-743-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-743-7_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9844-8

  • Online ISBN: 978-1-59259-743-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation